Celecoxib Uses, Dose, Side effects, & Brands

Celecoxib is a selective COX-2 inhibitor that inhibits the formation of prostaglandins resulting in anti-inflammatory, antipyretic, and analgesic effects. Unlike the non-selective non-steroidal anti-inflammatory drugs (NSAIDS) (e.g. ibuprofen and aceclofenac acid), it does not cause gastrointestinal upset such as gastritis.

It is used to treat the following conditions:

  • For the Management of acute pain

  • For pain and inflammation associated with Ankylosing spondylitis

  • For the relief of pain and inflammation in patients 2 years of age or older with Juvenile idiopathic arthritis

  • For the symptomatic treatment of Osteoarthritis

  • For the treatment of Primary dysmenorrhea

  • For inflammation and pain associated with Rheumatoid arthritis

Celecoxib Dose in Adults

  • A General Note about Celecoxib:

    • Use the lowest possible dose
    • Use for the shortest possible time
    • Avoid at best in patients with cardiovascular disease
    • Avoid in patients with heart failure.

  • Use of Celecoxib in the treatment of Acute pain or primary dysmenorrhea:

    • 400 mg as the initial dose followed by 200 mg additionally if needed on day 1.
    • Continue with a maintenance dose of 200 mg two times a day as needed.

  • Use of Celecoxib in the treatment of Ankylosing spondylitis:

    • 200 mg once a day or 100 mg two times a day.
    • The dose may be increased to 400 mg per day after six weeks if required.
    • If the drug is not effective after 6 weeks in a dose of 400 mg per day, alternate therapies may be tried.

  • Off label use as an alternative agent in the treatment of acute flare of Gouty arthritis:

    • 200 mg two times a day for the usual duration of 5 - 7 days
    • It should be initiated within 24 - 48 hours of flare onset.
    • Therapy should be discontinued 2 - 3 days after the resolution of symptoms.

  • Use in the Treatment of Osteoarthritis:

    • 200 mg once a day or
    • 100 mg two times a day.
  • Use in the treatment of Rheumatoid arthritis:

    • 100 - 200 mg two times a day.

Celecoxib Dose in Childrens

Dose in Juvenile idiopathic arthritis (JIA):

  • Children older than 2 years and Adolescents weighing 10 - 25 kgs:
    • 50 mg two times a day.
  • weight of more than 25 kgs:
    • 100 mg two times a day.

Pregnancy Risk Factor C if less than than 30 weeks gestation

Pregnancy Risk Factor D if more than 30 weeks gestation

  • Celecoxib, as with other NSAIDs is associated nonteratogenic results, such as the prenatal closing of ductus Arteriosus, persistent pulmonary Hypertension of the newborn (PPH), oligohydramnios and renal dysfunction or failure.
  • It should not be used in autoimmune rheumatic conditions.
  • Studies have also linked it to infertility, miscarriages and other problems.

Celecoxib use duringBreastfeeding:

  • Celecoxib can be found in breast milk in small amounts. It is compatible with breastfeeding.
  • Patients taking anticoagulants, low platelets count or platelet dysfunction should be cautious.

Celecoxib Dose in Renal Disease:

  • Mild to moderate renal impairment:
    • The manufacturer does not recommend any dose adjustment, however, renal functions should be monitored.
  • Severe renal impairment:
    • Not recommended in severe renal disease.
  • In addition, celecoxib should be discontinued in patients who develop renal dysfunction following its use and have a persistently abnormal or worsening renal dysfunction.

Celecoxib dose in Liver Disease:

  • Mild hepatic impairment (Child-Pugh class A):

    • Dose adjustment is not necessary;
  • Moderate impairment (Child-Pugh class B):

    • Reduce the dose by half.
  • Severe impairment (Child-Pugh class C):

    • It is contraindicated in patients with severe liver disease.
  • Persistent or worsening liver function tests:

    • Therapy should be discontinued.

Common Side Effects Of Celecoxib include:

  • Dermatologic:

    • Acute generalized exanthematous pustulosis
    • Exfoliative dermatitis
  • Gastrointestinal:

    • Gastrointestinal perforation
    • Gastrointestinal ulcer
    • GI inflammation
    • Intestinal perforation
  • Hypersensitivity:

    • Anaphylaxis
  • Immunologic:

    • DRESS syndrome
  • Respiratory:

  • Local alveolar osteitis (post oral surgery patients)

Less Common Side Effects of Celecoxib include:

  • Cardiovascular:

    • Peripheral edema
  • Gastrointestinal:

    • Diarrhea
    • Dyspepsia
    • Abdominal pain
    • Flatulence
    • Gastroesophageal reflux disease
    • Vomiting
  • Hepatic:

    • Increased liver enzymes
  • Renal:

    • Nephrolithiasis
  • Respiratory:

    • Upper respiratory tract infection
    • Sinusitis
    • Pharyngitis
    • Rhinitis
    • Dyspnea
  • Miscellaneous:

    • Accidental injury

Contraindication to Celecoxib include:

  • Allergic reaction to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation
  • Patients suffering from NSAID- or aspirin-induced allergies, asthma, or urticaria.
  • CABG surgery is performed.
  • The third trimester is when you can expect to have a baby
  • Breastfeeding women
  • Heart failure that is severe and not compensable
  • Duodenal or active gastric ulcer
  • Active gastrointestinal bleeding
  • Inflammatory bowel disease
  • Active hepatitis or decompensated liver disease
  • Grave renal impairment, CrCl less than 30mL/minute
  • Hyperkalemia
  • Patients under 18 years old

Warnings and Precautions

  • Anaphylactoid reactions
    • Angioedema and anaphylactic reactions may occur in patients who are taking the aspirin-triad (Asthma/rhinitis and aspirin intolerance).
  • Cardiovascular events [US Boxed Warning]
    • Celecoxib and other NSAIDs may increase your risk of cardiovascular events such as stroke or myocardial infarction.
    • Patients with a history of cardiovascular disease or other risk factors are at greater risk.
    • NSAIDs can also affect the response to ACE inhibitors or thiazide diuretics.
    • It can cause fluid retention and sodium buildup. Patients with heart failure should avoid it.
  • Gastrointestinal events: [US Boxed Warning]
    • The increased risk of gastrointestinal bleeding and ulceration from NSAIDs can lead to perforation, which could be fatal.
    • Patients with a history of peptic ulcer disease, gastrointestinal bleeding or elderly patients are at higher risk.
    • Patients taking anticoagulants, steroids and SSRIs with their medications are at greater risk for serious GI bleeding.
    • Patients at higher risk for GI bleeding are the elderly, smokers and alcoholics as well as patients with multiple comorbidities.
  • Hematologic effects
    • Anemia should be checked in patients receiving long-term therapy.
    • It doesn't affect the platelet count nor the coagulation profile.
    • Celecoxib at the appropriate doses does not inhibit platelet accumulation
  • Reactions to skin:
  • Allergy to sulfonamide (sulfa):
    • Cross-sensitivity to sulfonamide antibiotics is a concern. Celecoxib should not be used by patients with severe allergic reactions to sulfonamide anti-biotics.
  • Asthma
    • Aspirin-sensitive asthma patients should be advised to avoid it.
  • Coronary bypass surgery for coronary artery bypass graft: [US Boxed Warning]
    • Celecoxib should not be used in conjunction with CABG (coronary bypass graft surgery). It may increase the risk for stroke and myocardial damage.
    • Patients with Cytochrome P450 deficiency of Cytochrome 2C9 should be cautious.
  • Hepatic impairment
    • Patients with severe liver disease should avoid it and patients with moderate hepatic impairment should use it with caution. 
    • It is important to monitor the liver function of patients on a regular basis.
  • Renal impairment
    • NSAIDs can cause a decrease in renal blood flow, which may lead to renal injury, or worsen a previously existing renal injury, especially in patients who have hypotension, heart disease, heart failure, and patients with hypotension.
    • Long-term therapy can lead to pappillary necrosis.

Celecoxib: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).

5-Aminosalicylic Acid Derivatives Nonsteroidal anti-inflammatory agents may increase the nephrotoxic effects of 5-Aminosalicylic acid derivatives.
Ajmaline Sulfonamides can increase the toxic/adverse effects of Ajmaline. Particularly, there may be an increase in the risk of cholestasis.
Alcohol (Ethyl) This combination may increase the toxic/adverse effects of Nonsteroidal Anti-Inflammatory Drugs. This combination may increase the risk of GI bleeding.
Aliskiren Aliskiren's antihypertensive effects may be diminished by nonsteroidal Anti-Inflammatory agents. Aliskiren's nephrotoxic effects may be augmented by nonsteroidal anti-inflammatory agents. Patients receiving aliskiren or any other nonsteroidal anti-inflammatory drug should be monitored regularly. Pre-existing or elderly patients are at higher risk for renal dysfunction.
Aminoglycosides Nonsteroidal anti-inflammatory agents may reduce the excretion Aminoglycosides. Only data available in infants who are premature.
Aminolevulinic Acid Topical Photosensitizing agents may increase the photosensitizing effects of Aminolevulinic Acid Topical.
Angiotensin II Receptor Blockers Can increase the toxic/adverse effects of Nonsteroidal AntiInflammatory Agents. The combination could result in a significant decrease of renal function. Nonsteroidal anti-inflammatory agents may decrease the therapeutic effects of Angiotensin II Receptor Blockers. Combining these two agents can also reduce glomerular filtration, and may even improve renal function.
Angiotensin-Converting Enzyme Inhibitors Can increase the toxic/adverse effects of Nonsteroidal Anti-Inflammatory Drugs. The combination could result in a significant decrease of renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.
Anticoagulants Nonsteroidal anti-inflammatory agents may increase the anticoagulant effects of Anticoagulants.
ARIPiprazole CYP2D6 inhibitors (Weak), may increase serum levels of ARIPiprazole. Monitoring for increased aripiprazole-pharmacologic effects is important. Aripiprazole dosage adjustments may be necessary depending on the indication and concomitant therapy. For more information, consult the full interaction monograph.
Beta-Blockers Nonsteroidal anti-inflammatory agents may decrease the antihypertensive effects of Beta-Blockers. Levobunolol and Metipranolol are exceptions.
Bisphosphonate Derivatives Nonsteroidal anti-inflammatory agents may increase the toxic/adverse effects of Bisphosphonate derivatives. There is a greater risk of gastrointestinal bleeding and a higher risk of nephrotoxicity.
Corticosteroids (Systemic) May increase the toxic/adverse effects of Nonsteroidal AntiInflammatory Agents. (COX-2 Selective).
Moderate CYP2C9 Inducers Could lower the serum concentration of CYP2C9 substrates (High Risk with Inducers).
Moderate CYP2C9 Inhibitors Might decrease metabolism of CYP2C9 substrates (High Risk with Inhibitors).
Dapsone (Topical) May increase the toxic/adverse effects of Methemoglobinemia Associated Agents.
Deferasirox Nonsteroidal Anti-Inflammatory agents (NSA) may increase the toxic/adverse effects of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.
Desmopressin Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the toxic/adverse effects of Desmopressin.
Digoxin The serum Digoxin concentration may be increased by nonsteroidal anti-inflammatory agents.
Drospirenone Drospirenone's hyperkalemic effects may be enhanced by nonsteroidal anti-inflammatory agents.
Eplerenone Nonsteroidal Anti-Inflammatory agents may decrease Eplerenone's antihypertensive effects. Nonsteroidal Anti-Inflammatory agents may increase the hyperkalemic effects of Eplerenone.
Estrogen Derivatives Nonsteroidal Anti-Inflammatory agents (COX-2 Selective), may increase the thrombogenic effects of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents COX-2 Selective may increase Estrogen Derivatives' serum levels.
Felbinac Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Haloperidol Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the toxic/adverse effects of Haloperidol. This includes confusion and drowsiness.
HydrALAZINE HydrALAZINE's antihypertensive effects may be diminished by nonsteroidal anti-inflammatory agents.
Local Anesthesia Methemoglobinemia Associated agents may increase the harmful/toxic effects of Local Anesthestics. Methemoglobinemia risk may increase.
Lumacaftor May lower the serum concentrations of CYP2C9 substrates (High risk with inhibitors or inducers). Lumacaftor could increase serum concentrations of CYP2C9 substrates (High-Risk with Inhibitors and Inducers).
Naftazone May increase the antiplatelet effects of nonsteroidal anti-inflammatory agents.
Nitric Oxide May increase the toxic/adverse effect of Methemoglobinemia Associated Agents. Combinations of these agents can increase the risk of methemoglobinemia. When nitric dioxide is combined with other agents that can cause methemoglobinemia, it is important to monitor patients for signs such as hypoxia and cyanosis. Avoid lidocaine/prilocaine.
Perhexiline Perhexiline serum concentration may be increased by CYP2D6 inhibitors (Weak).
Porfimer Photosensitizing agents may increase the photosensitizing effects of Porfimer.
Potassium-Sparing Diuretics Nonsteroidal Anti Inflammatory Agents can decrease the antihypertensive effects of Potassium–Sparing Diuretics. Nonsteroidal Anti Inflammatory Agents can increase the hyperkalemic effects of Potassium–Sparing Diuretics.
PRALAtrexate PRALATREXATE may be increased by nonsteroidal anti-inflammatory agents (NSAIDS). Specifically, NSAIDS can decrease renal excretion. Monitoring: Keep an eye out for elevated pralatrexate levels or toxicity if a NSAID is used in conjunction. Monitoring for decreased pralatrexate levels after discontinuation of NSAIDs is a good idea.
Prilocaine Methemoglobinemia Associated Agents can increase the toxic/adverse effects of Prilocaine. Combinations with these agents can increase the risk of methemoglobinemia. When prilocaine is combined with other agents that can cause methemoglobinemia, monitor patients for signs such as hypoxia and cyanosis. Lidocaine/prilocaine should not be given to infants who are receiving these agents.
Probenecid Increases the serum concentrations of nonsteroidal anti-inflammatory agents.
Prostaglandins Ophthalmic Nonsteroidal Anti Inflammatory Agents can decrease the therapeutic effects of Prostaglandins Ophthalmic. Nonsteroidal Anti Inflammatory Agents can also increase the therapeutic effect of Prostaglandins Ophthalmic.
Quinolones Nonsteroidal Anti Inflammatory Agents can increase the neuroexcitatory or seizure-potentiating effects of Quinolones. Nonsteroidal Anti-Inflammatory agents may increase Quinolones' serum levels.
Rifapentine Could lower the serum concentration of CYP2C9 substrates (High Risk with Inducers).
Selective Serotonin Reuptake inhibitors Nonsteroidal Anti-Inflammatory Agents (COX-2 selective) may have an increased antiplatelet action. Nonsteroidal Anti-Inflammatory Agents COX-2 Selective may decrease the therapeutic effect of Selective Selotonin Reuptake Inhibitors.
Sodium Nitrite Methemoglobinemia Associated Agents can increase the toxic/adverse effect of Sodium Nitrite. Combinations of these agents could increase the chance of significant methemoglobinemia.
Tacrolimus (Systemic) Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the nephrotoxic effects of Tacrolimus.
Thiazide and Thiazide -Like Diuretics Nonsteroidal Anti-Inflammatory Agents may have a greater nephrotoxic impact. Nonsteroidal Anti-Inflammatory agents may decrease the therapeutic effects of Thiazide or Thiazide-Like Diuretics.
Tolperisone Tolperisone's toxic/adverse effects may be exacerbated by nonsteroidal anti-inflammatory agents. Hypersensitivity reactions, in particular, may increase. The therapeutic effects of Nonsteroidal Anti-Inflammatory Drugs may be enhanced by Tolperisone.
Tricyclic Antidepressants (Tertiary Amine). May increase the antiplatelet effects of nonsteroidal anti-inflammatory agents (COX-2 Selective).
Triflusal Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may reduce Triflusal's protein binding. Specifically, NSAIDs can decrease the protein binding to active Triflusal metabolite. Triflusal could decrease the protein binding to Nonsteroidal Anti-Inflammatory Drugs.
Vancomycin Vancomycin may be increased by nonsteroidal anti-inflammatory agents.
Verteporfin Photosensitizing agents may increase the photosensitizing effects of Verteporfin.
Vitamin K antagonists (eg warfarin) Nonsteroidal Anti-Inflammatory Agents COX-2 Selective may increase the anticoagulant effects of Vitamin K Antagonists. Nonsteroidal Anti-Inflammatory Agents, COX-2 Selective may increase Vitamin K Antagonists' serum levels.

Risk Factor D (Consider therapy modifications)

 
Aspirin Can increase the toxic/adverse effects of Nonsteroidal Anti-Inflammatory Drugs (COX-2 Selective). Management: It is not recommended to use aspirin in combination with cardioprotective doses. Concurrent use of low-dose aspirin and a COX-2 inhibitor with aspirin is allowed, but patients should be closely monitored for signs/symptoms such as GI ulceration/bleeding.
Bile Acid Sequestrants This may decrease the absorption rate of nonsteroidal anti-inflammatory agents.
CycloSPORINE Systemic CycloSPORINE Systemic may have a nephrotoxic effect due to nonsteroidal anti-inflammatory agents. CycloSPORINE Systemic may increase serum levels of Nonsteroidal Anti-Inflammatory agents. The serum concentration of CycloSPORINE Systemic may be increased by nonsteroidal anti-inflammatory agents. Management: Look for alternatives to nonsteroidal, anti-inflammatory drugs (NSAIDs). Monitor for signs of nephrotoxicity and elevated serum cyclosporine levels or systemic effects (eg hypertension) when NSAID therapy is combined.
Dabrafenib High risk of Inducers causing a decrease in serum CYP2C9 substrates. Management: If possible, seek alternatives to the CYP2C9 substrat. Concomitant therapy should be avoided if possible. Monitor the clinical effects of the substrate carefully (especially therapeutic effects).
Enzalutamide High risk of Inducers causing a decrease in serum concentrations of CYP2C9 substrates. Management: Avoid concurrent use of enzalutamide and CYP2C9 substrates with a narrow therapeutic index. You should exercise caution when using enzalutamide or any other CYP2C9 substrat.
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. There may be bleeding. Treatment: Avoid concurrent use of these agents. Concomitant use of these agents should be avoided.
Lithium The serum level of Lithium may be increased by nonsteroidal anti-inflammatory agents.
Loop Diuretics Loop Diuretics may have a less diuretic effect than nonsteroidal Anti-Inflammatory agents. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may have a greater nephrotoxic effect than Loop Diuretics. Monitoring: Look out for signs of kidney injury and decreased therapeutic effects from loop diuretics when used in conjunction with an NSAID. Avoid concurrent use of NSAIDs in CHF and cirrhosis. It is not recommended to use bumetanide and indomethacin together.
Methotrexate The serum Methotrexate concentration may be increased by nonsteroidal anti-inflammatory agents. Management: If the patient is currently receiving high doses of Methotrexate, it is important to consider alternative anti-inflammatory therapies.
MiFEPRIStone High risk of Inhibitors causing an increase in serum CYP2C9 substrates. Management: Keep CYP2C9 Substrates at the lowest dose and closely monitor for adverse reactions during and after mifepristone treatment.
Sincalide Sincalide may be less effective if drugs that affect gallbladder function are taken. Management: Before Sincalide is used to stimulate the gallbladder, discontinue any drugs that affect gallbladder motility.
Sodium Phosphates Nonsteroidal Anti-Inflammatory Agents may have a greater nephrotoxic impact. In particular, acute phosphate neuropathy could be increased. Management: You can avoid this combination by temporarily stopping treatment with NSAIDs or looking for alternatives to oral sodium phosphate bowel prep. Maintain adequate hydration, and closely monitor your renal function if the combination is not possible.
Tenofovir Products Tenofovir Products may have a nephrotoxic effect that is enhanced by nonsteroidal anti-inflammatory agents. Management: If possible, look for alternatives to these combinations. Avoid tenofovir combination with other NSAIDs, or any NSAID that is given in a high dosage.

Risk Factor X (Avoid Combination)

 
Acemetacin Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Aminolevulinic Acid Systemic The photosensitizing effects of Aminolevulinic Acid Systemic may be enhanced by the use of photosensitizing agents.
Dexibuprofen Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the toxic/adverse effects of Dexibuprofen.
Dexketoprofen Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Floctafenine Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Ketorolac, (Nasal). Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Ketorolac Systemic Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Macimorelin Nonsteroidal Anti-Inflammatory Drugs (NSA) may reduce the diagnostic effectiveness of Macimorelin.
Mecamylamine Sulfonamides can increase the toxic/adverse effects of Mecamylamine.
Mifamurtide Nonsteroidal anti-inflammatory agents (NSA) may reduce the therapeutic effects of Mifamurtide.
Morniflumate Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Nonsteroidal Anti-Inflammatory Drugs May increase the toxic/adverse effects of nonsteroidal anti-inflammatory agents (COX-2 Selective).
Nonsteroidal Anti-Inflammatory Agents COX-2 Selective Nonsteroidal Anti-Inflammatory agents (COX-2 Selective) may have a greater adverse/toxic impact than nonsteroidal Anti-Inflammatory Drugs.
Omacetaxine Omacetaxine's toxic/adverse effects may be exacerbated by nonsteroidal anti-inflammatory agents. In particular, bleeding-related events could be more common. Patients with a platelet count below 50,000/uL should not use omacetaxine and nonsteroidal anti-inflammatory drugs (NSAIDs).
Pelubiprofen Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Phenylbutazone Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Talniflumate Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Tenoxicam Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.
Zaltoprofen Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact.

Monitor:

  • CBC
  • Liver functions tests
  • Renal function tests & Metabolic profile
  • Observe for occult blood loss and dyspepsia
  • Monitor response to treatment including pain, mobility, range of movements, grip strength, and features of inflammation
  • Blood pressure at baseline and during treatment
  • Observe for weight gain & edema

JIA: Monitor for development of abnormal coagulation tests with systemic onset JIA

How to Administer Celecoxib?

  • Celecoxib may be taken with or without regard to meals.
  • It may be swallowed whole or its contents sprinkled onto applesauce or emptied onto a teaspoon of cool or room temperature applesauce and administered immediately with water.

Mechanism of action of Celecoxib:

  • It has antipyretic, anti-inflammatory, and analgesic effects.

Slowly, it isabsorbedIt is 97% bound with proteins.

It isMetabolizedThe liver converts inactive metabolites via CYP2c9 

Thehalf-life eliminationThe average time it takes to get the drug into children and adolescents is six hours, while adults can take it for up to 11 hours.

TheTime to reach peakThe serum concentration takes 3 hours. 

It isexcretedPrimarily via feces peak.

International brand names of Celecoxib:

  • ACCEL-Celecoxib
  • ACT Celecoxib
  • AG-Celecoxib
  • APO-Celecoxib
  • Auro-Celecoxib
  • BIO-Celecoxib
  • CeleBREX
  • GD-Celecoxib
  • JAMP-Celecoxib
  • Mar-Celecoxib
  • MINT-Celecoxib
  • MYLAN-Celecoxib
  • PMS-Celecoxib
  • Priva-Celecoxib
  • RAN-Celecoxib
  • RIVA-Celecox
  • SANDOZ Celecoxib
  • SDZ Celecoxib
  • TEVA-Celecoxib
  • Acicox
  • Aclexa
  • Algoxib
  • Artilog
  • Artose
  • Arythrex
  • Aubrex
  • Brexen
  • Caditar
  • Cecox
  • Celbexx
  • Celbric
  • Celcox
  • Celcoxx
  • Cele V
  • Celebex
  • Celebone
  • Celebra
  • Celebrex
  • Celecox
  • Celecsil
  • Celenta
  • Celexib
  • Celexil
  • Celib
  • Celofen
  • Celoxib
  • Celxib
  • Celzib
  • Cerebrex
  • Colcibid
  • Colcibra
  • Cox-2
  • Coxib
  • Coxileb
  • Coxoral
  • Coxzan
  • Eliflam
  • Eurocox
  • Ezy
  • Flamar
  • Flamex
  • Flaxel
  • Flogoxib
  • Geocoxib
  • Icox
  • Keltrex
  • Letabex
  • Lexfin
  • Mecelxib
  • Mibecerex
  • Miodar
  • Nacoxib
  • Onsenal
  • Painex
  • Rancelex
  • Ranselex
  • Relexa
  • Revcox
  • Roxib
  • Selexa
  • Stadloric
  • Stadloric 200
  • Unicelib
  • Valdyne
  • Zecroxil
  • Zobrex
  • Zycel

Celecoxib brands in Pakistan:

Celecoxib [Tabs 100 Mg]

Artocel Honig Pharmaceuticals Laboratories
Celconid Caraway Pharmaceuticals
Ecoloxib Navegal Laboratories
Medicoxib Mediceena Pharma (Pvt) Ltd.
Osteoxib Zesion Pharmaceutical (Pvt) Ltd
Sancel Robins Pharmaceutical Industries
Sefecox Pharmevo (Pvt) Ltd.
Seleco Wilshire Laboratories (Pvt) Ltd.
Shexib Everest Pharmaceuticals
Shexib Everest Pharmaceuticals

Celecoxib [Tabs 200 Mg]

Ecoloxib Navegal Laboratories
Emphatic Hygeia Pharmaceuticals
Osteoxib Zesion Pharmaceutical (Pvt) Ltd
Postaglin Medicraft Pharmaceuticals (Pvt) Ltd.
Sancel Robins Pharmaceutical Industries
Sefecox Pharmevo (Pvt) Ltd.
Seleco Wilshire Laboratories (Pvt) Ltd.
Shexib Everest Pharmaceuticals
Shexib Everest Pharmaceuticals

Celecoxib [Caps 100 Mg]

Articoxib Nabiqasim Industries (Pvt) Ltd.
Biox Vega Pharmaceuticals Ltd.
Bixo Vega Pharmaceuticals Ltd.
Bloxib Bloom Pharmaceuticals (Pvt) Ltd.
Celart Hilton Pharma (Pvt) Limited
Celbexx Getz Pharma Pakistan (Pvt) Ltd.
Cele Tg Pharma
Celecoxx Semos Pharmaceuticals (Pvt) Ltd.
Celetab Indus Pharma (Pvt) Ltd.
Celmax Max Pharmaceuticals
Celoxib The Schazoo Laboratories Ltd.
Celzib Well & Well Pharma (Pvt) Ltd
Ecoxib Epoch Pharmaceutical
Emphatic Hygeia Pharmaceuticals
Gauld Karachi Chemical Industries
Geocoxib Geofman Pharmaceuticals
Gilbex Genome Pharmaceuticals (Pvt) Ltd
Lecoxib Paramount Pharmaceuticals
Moveryl Sami Pharmaceuticals (Pvt) Ltd.
Nuzib Bosch Pharmaceuticals (Pvt) Ltd.
Osteocox Friends Pharma (Pvt) Ltd
Postaglin Medicraft Pharmaceuticals (Pvt) Ltd.
Rheuoxib Highnoon Laboratories Ltd.
Rival Kurative Pak (Pvt) Ltd
Seloxx Efroze Chemical Industries (Pvt) Ltd.
Unicoxib Tg Pharma

 

Celecoxib [Caps 200 Mg]

Articoxib Nabiqasim Industries (Pvt) Ltd.
Artiflex Standpharm Pakistan (Pvt) Ltd.
Biox Vega Pharmaceuticals Ltd.
Bixo Vega Pharmaceuticals Ltd.
Bloxib Bloom Pharmaceuticals (Pvt) Ltd.
Celart Hilton Pharma (Pvt) Limited
Celbexx Getz Pharma Pakistan (Pvt) Ltd.
Cele Tg Pharma
Celecomed Mediate Pharmaceuticals (Pvt) Ltd
Celecoxx Semos Pharmaceuticals (Pvt) Ltd.
Celetab Indus Pharma (Pvt) Ltd.
Celewin Wns Field Pharmaceuticals
Celicob Mass Pharma (Private) Limited
Celmatic Aptcure Private Limited
Celmax Max Pharmaceuticals
Celoxib The Schazoo Laboratories Ltd.
Celstar Pharmatec Pakistan (Pvt) Ltd.
Celtex Panacea Pharmaceuticals
Celtic Genome Pharmaceuticals (Pvt) Ltd
Celzib Well & Well Pharma (Pvt) Ltd
Cobix Eg Pharmaceuticals
Cobix Eg Pharmaceuticals
Coxban Rakaposhi Pharmaceutical (Pvt) Ltd.
Coxgen Genome Pharmaceuticals (Pvt) Ltd
Dorsiflex Consolidated Chemical Laboratories (Pvt) Ltd.
Dorsiflex Consolidated Chemical Laboratories (Pvt) Ltd.
Ecoxib Epoch Pharmaceutical
Gauld Karachi Chemical Industries
Geocoxib Geofman Pharmaceuticals
Gilbex Genome Pharmaceuticals (Pvt) Ltd
Lecoxib Paramount Pharmaceuticals
Markzib Welmark Pharmaceuticals
Moveryl Sami Pharmaceuticals (Pvt) Ltd.
Nuzib Bosch Pharmaceuticals (Pvt) Ltd.
Rheuoxib Highnoon Laboratories Ltd.
Seloxx Efroze Chemical Industries (Pvt) Ltd.
Selxib Fynk Pharmaceuticals
Sixib Siam Pharmaceuticals
Thiocid Rogen Pharmaceuticals
Unicoxib Tg Pharma
Wecox Wise Pharmaceuticals (Pvt) Ltd

Comments

NO Comments Found